Browse NR4A2

Summary
SymbolNR4A2
Namenuclear receptor subfamily 4, group A, member 2
Aliases TINUR; HZF-3; NURR1; NGFI-B/nur77 beta-type transcription factor homolog; T-cell nuclear receptor NOT; immed ......
Chromosomal Location2q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Nucleus. Note=Mostly nuclear; oxidative stress promotes cytoplasmic localization.
Domain PF00104 Ligand-binding domain of nuclear hormone receptor
PF00105 Zinc finger
Function

Transcriptional regulator which is important for the differentiation and maintenance of meso-diencephalic dopaminergic (mdDA) neurons during development. It is crucial for expression of a set of genes such as SLC6A3, SLC18A2, TH and DRD2 which are essential for development of mdDA neurons (By similarity).

> Gene Ontology
 
Biological Process GO:0001666 response to hypoxia
GO:0001764 neuron migration
GO:0001975 response to amphetamine
GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006584 catecholamine metabolic process
GO:0006979 response to oxidative stress
GO:0007409 axonogenesis
GO:0007585 respiratory gaseous exchange
GO:0007626 locomotory behavior
GO:0008344 adult locomotory behavior
GO:0009308 amine metabolic process
GO:0009712 catechol-containing compound metabolic process
GO:0009713 catechol-containing compound biosynthetic process
GO:0009755 hormone-mediated signaling pathway
GO:0009791 post-embryonic development
GO:0009991 response to extracellular stimulus
GO:0014075 response to amine
GO:0016055 Wnt signaling pathway
GO:0018958 phenol-containing compound metabolic process
GO:0021536 diencephalon development
GO:0021538 epithalamus development
GO:0021700 developmental maturation
GO:0021952 central nervous system projection neuron axonogenesis
GO:0021953 central nervous system neuron differentiation
GO:0021954 central nervous system neuron development
GO:0021955 central nervous system neuron axonogenesis
GO:0021986 habenula development
GO:0030522 intracellular receptor signaling pathway
GO:0030534 adult behavior
GO:0030900 forebrain development
GO:0030901 midbrain development
GO:0031668 cellular response to extracellular stimulus
GO:0033238 regulation of cellular amine metabolic process
GO:0033555 multicellular organismal response to stress
GO:0034599 cellular response to oxidative stress
GO:0036293 response to decreased oxygen levels
GO:0042053 regulation of dopamine metabolic process
GO:0042069 regulation of catecholamine metabolic process
GO:0042416 dopamine biosynthetic process
GO:0042417 dopamine metabolic process
GO:0042423 catecholamine biosynthetic process
GO:0042551 neuron maturation
GO:0043401 steroid hormone mediated signaling pathway
GO:0043434 response to peptide hormone
GO:0043435 response to corticotropin-releasing hormone
GO:0043523 regulation of neuron apoptotic process
GO:0043524 negative regulation of neuron apoptotic process
GO:0043576 regulation of respiratory gaseous exchange
GO:0044106 cellular amine metabolic process
GO:0044708 single-organism behavior
GO:0045444 fat cell differentiation
GO:0046189 phenol-containing compound biosynthetic process
GO:0048469 cell maturation
GO:0048545 response to steroid hormone
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0051402 neuron apoptotic process
GO:0051866 general adaptation syndrome
GO:0060070 canonical Wnt signaling pathway
GO:0061564 axon development
GO:0070482 response to oxygen levels
GO:0070997 neuron death
GO:0071375 cellular response to peptide hormone stimulus
GO:0071376 cellular response to corticotropin-releasing hormone stimulus
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071496 cellular response to external stimulus
GO:0071542 dopaminergic neuron differentiation
GO:0198738 cell-cell signaling by wnt
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1901615 organic hydroxy compound metabolic process
GO:1901617 organic hydroxy compound biosynthetic process
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1904948 midbrain dopaminergic neuron differentiation
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
Molecular Function GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003707 steroid hormone receptor activity
GO:0004879 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding
GO:0008013 beta-catenin binding
GO:0008134 transcription factor binding
GO:0035257 nuclear hormone receptor binding
GO:0035258 steroid hormone receptor binding
GO:0035259 glucocorticoid receptor binding
GO:0042974 retinoic acid receptor binding
GO:0046965 retinoid X receptor binding
GO:0046982 protein heterodimerization activity
GO:0051427 hormone receptor binding
GO:0098531 transcription factor activity, direct ligand regulated sequence-specific DNA binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-383280: Nuclear Receptor transcription pathway
Summary
SymbolNR4A2
Namenuclear receptor subfamily 4, group A, member 2
Aliases TINUR; HZF-3; NURR1; NGFI-B/nur77 beta-type transcription factor homolog; T-cell nuclear receptor NOT; immed ......
Chromosomal Location2q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NR4A2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between NR4A2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
16293616Colorectal CarcinomaInhibit immunityFinally, functional studies reveal that PGE2-mediated protection from apoptosis is completely inhibited by a dominant-negative NR4A2 construct. These most recent data suggest that NR4A2, a member of another family of nuclear receptors can stimulate progression of colorectal cancer downstream from cyclooxygenase 2-derived PGE2.
Summary
SymbolNR4A2
Namenuclear receptor subfamily 4, group A, member 2
Aliases TINUR; HZF-3; NURR1; NGFI-B/nur77 beta-type transcription factor homolog; T-cell nuclear receptor NOT; immed ......
Chromosomal Location2q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NR4A2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNR4A2
Namenuclear receptor subfamily 4, group A, member 2
Aliases TINUR; HZF-3; NURR1; NGFI-B/nur77 beta-type transcription factor homolog; T-cell nuclear receptor NOT; immed ......
Chromosomal Location2q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NR4A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.170.737
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.610.67
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.7530.421
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6160.314
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5970.772
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6350.818
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2040.604
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.6150.559
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3410.746
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1120.854
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1720.836
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1250.556
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NR4A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117011.8-11.80.193
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)1311018.2-18.20.199
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNR4A2
Namenuclear receptor subfamily 4, group A, member 2
Aliases TINUR; HZF-3; NURR1; NGFI-B/nur77 beta-type transcription factor homolog; T-cell nuclear receptor NOT; immed ......
Chromosomal Location2q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NR4A2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNR4A2
Namenuclear receptor subfamily 4, group A, member 2
Aliases TINUR; HZF-3; NURR1; NGFI-B/nur77 beta-type transcription factor homolog; T-cell nuclear receptor NOT; immed ......
Chromosomal Location2q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NR4A2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NR4A2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNR4A2
Namenuclear receptor subfamily 4, group A, member 2
Aliases TINUR; HZF-3; NURR1; NGFI-B/nur77 beta-type transcription factor homolog; T-cell nuclear receptor NOT; immed ......
Chromosomal Location2q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NR4A2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNR4A2
Namenuclear receptor subfamily 4, group A, member 2
Aliases TINUR; HZF-3; NURR1; NGFI-B/nur77 beta-type transcription factor homolog; T-cell nuclear receptor NOT; immed ......
Chromosomal Location2q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NR4A2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNR4A2
Namenuclear receptor subfamily 4, group A, member 2
Aliases TINUR; HZF-3; NURR1; NGFI-B/nur77 beta-type transcription factor homolog; T-cell nuclear receptor NOT; immed ......
Chromosomal Location2q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NR4A2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNR4A2
Namenuclear receptor subfamily 4, group A, member 2
Aliases TINUR; HZF-3; NURR1; NGFI-B/nur77 beta-type transcription factor homolog; T-cell nuclear receptor NOT; immed ......
Chromosomal Location2q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NR4A2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.